BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31214915)

  • 1. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
    Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J
    Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses.
    Dono A; Vu J; Anapolsky M; Hines G; Takayasu T; Yan Y; Tandon N; Zhu JJ; Bhattacharjee MB; Esquenazi Y; Ballester LY
    J Neurooncol; 2020 Sep; 149(3):463-472. PubMed ID: 33009979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.
    Aisner DL; Newell KL; Pollack AG; Kleinschmidt-Demasters BK; Steinberg GK; Smyth LT; Vogel H
    Clin Neuropathol; 2014; 33(2):112-21. PubMed ID: 24321241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of targeting
    Smith-Cohn M; Davidson C; Colman H; Cohen AL
    CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
    [No Abstract]   [Full Text] [Related]  

  • 8. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 9. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
    Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
    Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
    Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
    Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI characteristics predict BRAF V600E status in gangliogliomas and pleomorphic xanthoastrocytomas and provide survival prognostication.
    Jiang B; Zheng Y; She D; Xing Z; Cao D
    Acta Radiol; 2024 Jan; 65(1):33-40. PubMed ID: 37401109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Significance of
    Prieto R; Barrios L; Ebrat-Mancilla E; Martín P; Tejerina E
    Int J Surg Pathol; 2024 Jun; 32(4):649-666. PubMed ID: 37743598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    Vizcaino MA; Giannini C; Lalich D; Nael A; Jenkins RB; Tran Q; Orr BA; Abdullaev Z; Aldape K; Vaubel RA
    J Neuropathol Exp Neurol; 2024 May; 83(6):416-424. PubMed ID: 38699943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
    Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    Xi S; Huang Q; Zeng J
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological characteristics of gangliogliomas with anaplastic morphology].
    Guo LA; Wang LM; Fu YJ; Luo T; Fan XT; Zhao LH; Yao XH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):585-591. PubMed ID: 38825904
    [No Abstract]   [Full Text] [Related]  

  • 18. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
    Dougherty MJ; Santi M; Brose MS; Ma C; Resnick AC; Sievert AJ; Storm PB; Biegel JA
    Neuro Oncol; 2010 Jul; 12(7):621-30. PubMed ID: 20156809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations.
    Wang AC; Jones DTW; Abecassis IJ; Cole BL; Leary SES; Lockwood CM; Chavez L; Capper D; Korshunov A; Fallah A; Wang S; Ene C; Olson JM; Geyer JR; Holland EC; Lee A; Ellenbogen RG; Ojemann JG
    Mol Cancer Res; 2018 Oct; 16(10):1491-1498. PubMed ID: 30006355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment with Dabrafenib/Trametinib of a Malignantly Transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: A Case Report and Review of the Literature.
    Vermeulen E; Vander Mijnsbrugge AS; Brock S; Vaeyens F; Dirven I; Ciçek A; Marcelis W; Klein S; Bruneau M; Neyns B; Duerinck J
    Case Rep Oncol; 2024; 17(1):10-16. PubMed ID: 38179547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.